Half-Year 2022 Financial and Clinical Trials Update

Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Phase/study # of patients Design ■ 1L ctDNA high risk DLBCL Phase II N=40 Glofitamab plus R-CHOP (glofitamab is introduced as a consolidation to R-CHOP at cycle 3-8 in patients ctDNA+ at cycle 2) " EOT PET-CR Primary endpoint Status CT Identifier FPI Q1 2022 NCT04980222 ctDNA-circulating tumor DNA; DLBCL-diffuse large B cell lymphoma; R-CHOP=Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone; PET=positron emission tomography; EOT PET-CR-End of treatment PET- complete response rate 133 Roche Oncology

View entire presentation